01:38:24 EDT Tue 28 Jun 2022
Enter Symbol
or Name

Login ID:
Canntab Therapeutics Ltd
Symbol PILL
Shares Issued 32,867,124
Close 2020-09-21 C$ 0.75
Recent Sedar Documents

Canntab receives U.S. patent for multilayer tablets

2020-09-21 10:43 ET - News Release

Mr. Larry Latowsky reports


Pursuant to a filing made in March, 2017, the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,772,837 to Canntab Therapeutics Ltd., titled "Modified Release Multi-Layer Tablet Cannabinoid Formulations." The term of the patent expires on March 15, 2038.

Larry Latowsky, chief executive officer of Canntab, said: "This is a major milestone that confirms our proprietary formulations are unique and differentiated from other product offerings in the global marketplace, which will support a faster revenue stream as we begin production and distribution in the immediate future. This is the first patent that was issued to date out of the 13 that we have applied for, and will be leveraged to solidify Canntab's position as the leader in solid dose (hard pill) formulations of medicinal cannabinoids.

The patent granted is for Canntab's bilayer or multilayer tablets consisting of both instant release (IR) and extended release (XR) formulations with tetrahydrocannabinol, cannabidiol, and a variety of terpenes and other cannabinoids found in full-spectrum cannabis and hemp oil resin.

Canntab believes that its hard pill formulations are superior to all other CBD and THC delivery systems since they are true pharmaceutical-grade delivery systems that provide for superior ingredient stability, enhanced bioavailability, and provide customizable and precise dosing. Canntab believes and intends to prove greater bioavailability through a blood level study at a third party clinical research organization. In addition, whether it is for medical, recreational or nutraceutical purposes, Canntab is able to provide extended release formulations, making it the clear delivery choice for doctors, patients or the average consumer.

"Canntab expects this and future patents to be very valuable in the development of our strategic partnerships and alliances, and in our efforts to secure worldwide distribution of our proprietary products. As the medical community continues to recognize Cannabinoid alternatives to traditional therapies, we will continue to develop innovative approaches to support many clinical applications," continued Mr. Latowsky.

In addition, Canntab is conducting research to confirm its belief that its combined CBD and THC tablet can be effective to treat nicotine, alcohol, cannabis, opioid and other forms of addiction. Canntab will be using a derivative of these formulations for its clinical trial with Dr. Donald Garbuz from the University of British Columbia and as previously released in December, 2018. This study aims to demonstrate the potential for the reduction or elimination of the use of opiates in patients during postoperative pain management.

This issued patent covers Canntab's modified release pharmaceutical compositions and more specifically compositions comprising cannabinoids and a process for preparation thereof as well as methods for administering the compositions to human users. The compositions may contain a combination of ingredients in proportions calculated to achieve therapeutic effect.

Canntab has filed applications for 13 patents in Canada and the U.S. that cover a range of processes and formulations that it uses to create its precision oral-delivery hard tablets, the future of medical cannabis. These patents include Canntab's proprietary nano-emulsification technology, granulation process, methods of manufacturing and covers its full line of precision oral-delivery hard tablets including instant (immediate) release tablets, extended release tablets and oral dissolvable tablets. Canntab has also filed a patent for an exclusive formulation of THC and CBD for the treatment of opioid addiction treatment therapy.

About Canntab Therapeutics Ltd.

Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Long referred to as cannabis 3.0 by the company, Canntab's proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical-grade solutions, which incorporate all the features one would expect from any prescription or over-the-counter medication sold in pharmacies around the world. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability.

Canntab holds a cannabis standard processing and sales for medical purposes licence, a cannabis research licence, and an industrial hemp licence from Health Canada.

We seek Safe Harbor.

© 2022 Canjex Publishing Ltd. All rights reserved.